---
document_datetime: 2023-09-21 18:56:07
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/opgenra-epar-all-authorised-presentations_en.pdf
document_name: opgenra-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7975144
conversion_datetime: 2025-12-21 23:08:30.969448
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EU Number       | Invented name   | Strength   | Pharmaceutical Form                    | Route of Administration   | Packaging                                                                         | Content (concentration)   | Package size      |
|-----------------|-----------------|------------|----------------------------------------|---------------------------|-----------------------------------------------------------------------------------|---------------------------|-------------------|
| EU/1/08/489/001 | Opgenra         | 3.5 mg     | Powder for suspension for implantation | Implantation              | powder (eptotermin alfa): vial (glass/alu); powder (carmellose): vial (glass/alu) | 3.5 mg / 2.5 ml           | 1 vial + 1 vial   |
| EU/1/08/489/002 | Opgenra         | 3.5 mg     | Powder for suspension for implantation | Implantation              | powder (eptotermin alfa): vial (glass/alu); powder (carmellose): vial (glass/alu) | 3.5 mg / 2.5 ml           | 2 vials + 2 vials |

## Powder for suspension for implantation Implantation Medicinal product no longer authorised